Suggested remit: To appraise the clinical and cost effectiveness of pexidartinib within its marketing authorisation for treating symptomatic tenosynovial giant cell tumour.
Following on from information provided to NICE by the company in July 2020 the appraisal of Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1682

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
15 November 2022 Following on from information provided to NICE by the company in July 2020 the appraisal of Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
15 November 2022 Discontinued. Following on from information provided to NICE by the company in July 2020 the appraisal of Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
02 October 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of Pexidartinib for treating symptomatic tenosynovial giant cell tumour. However, the company have advised that The European Medicines Agency Committee for Medicinal Products (CHMP) have issued a negative opinion for Pexidartinib for treating symptomatic tenosynovial giant cell tumour adults in the European Union. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.
02 October 2020 Suspended. Topic has been suspended
07 May 2020 Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
16 March 2020 (14:00) Scoping workshop (Manchester)
21 January 2020 - 18 February 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual